Patients with inflammatory bowel disease (IBD) who require methotrexate (MTX)for treatment
currently receive this drug by injection. MTX is also available as a pill that can be given
by mouth but it is not known how well the drug enters the body in patients with Crohn's
disease or ulcerative colitis. This study is being done to compare how much MTX enters the
body when the drug is taken by mouth compared to when it is given by injection. If the drug
is well absorbed, it may allow patients to receive the drug by mouth.
- Adult or pediatric patients with IBD (CD or UC) currently receiving MTX as part of
their clinical care.
- Patients must be receiving weekly MTX at a dose between 7.5 and 40 mg/m2.
- Weight >= 12 kg.
- Normal serum creatinine.